Latest Pyrazines Stories
The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - today heralded the expansion of treatment options for previously untreated patients with multiple myeloma, giving patients in Canada and Europe access to drugs similar to what is available to patients in the United States.
Q. Last night, my boyfriend became so violent, I was afraid he was going to hit my 22-year-old daughter or me. He threatened to burn down our home, and he tried to kick me out. I just realized that he started changing in the past two weeks right after he started taking Chantix to quit smoking.
-- Elderly patients taking LUNESTA 2 mg showed significant improvements in measures of daytime function compared to placebo over a 12-week treatment period -- Elderly patients administered LUNESTA 2 mg showed no evidence of rebound insomnia and withdrawal symptoms were comparable to the placebo group upon discontinuation Sepracor Inc.
Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of LUNESTA(R) brand eszopiclone Phase IV study data at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona.
CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week's edition of the New England Journal of Medicine.
Telik has announced that its small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia.
SAN DIEGO, Aug. 18 /PRNewswire/ -- The next time you consider popping a pill when you have trouble nodding off, it might be worth counting sheep instead. A senior psychiatrist at the Scripps Clinic Sleep Center in San Diego, Calif.
Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients.
CAMBRIDGE, Mass., July 28 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the initiation of a Phase I trial series of MLN4924, the Company's first-in-class, small molecule inhibitor of the Millennium-discovered target, the Nedd 8 Activating Enzyme (NAE).
WASHINGTON, July 9 /PRNewswire-USNewswire/ -- In a congressional hearing Secretary of Veterans Affairs James B.
- Of or relating to good digestion.